Literature DB >> 2436042

Detection of c-rel-related transcripts in mouse hematopoietic tissues, fractionated lymphocyte populations, and cell lines.

E Brownell, B Mathieson, H A Young, J Keller, J N Ihle, N R Rice.   

Abstract

A portion of the human cellular homolog of v-rel, the transforming gene of the leukemogenic retrovirus reticuloendotheliosis virus, strain T, was used to survey RNAs from several mouse tissues, selected lymphocyte populations, and hematopoietic cell lines for c-rel expression. Relatively high levels of a high-molecular-weight transcript were observed in peripheral B and T cells, whereas lower levels were detectable in functionally immature thymocytes. These results suggested that, unlike c-myb and c-ets, the c-rel proto-oncogene plays a role in later stages of lymphocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2436042      PMCID: PMC365210          DOI: 10.1128/mcb.7.3.1304-1309.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  30 in total

1.  Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin.

Authors:  Y Reisner; M Linker-Israeli; N Sharon
Journal:  Cell Immunol       Date:  1976-07       Impact factor: 4.868

2.  Transcripts from the cellular homologs of retroviral oncogenes: distribution among chicken tissues.

Authors:  T J Gonda; D K Sheiness; J M Bishop
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

3.  Ribonucleic acid isolated by cesium chloride centrifugation.

Authors:  V Glisin; R Crkvenjakov; C Byus
Journal:  Biochemistry       Date:  1974-06-04       Impact factor: 3.162

4.  Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines.

Authors:  G Köhler; S C Howe; C Milstein
Journal:  Eur J Immunol       Date:  1976-04       Impact factor: 5.532

5.  Physicochemical, biological and serological properties of a leukemogenic virus isolated from cultured RadLV-induced lymphomas of C57BL/Ka mice.

Authors:  A Declève; M Lieberman; J N Ihle; P N Rosenthal; M L Lung; H S Kaplan
Journal:  Virology       Date:  1978-10-01       Impact factor: 3.616

6.  Avian reticuloendotheliosis virus contains a new class of oncogene of turkey origin.

Authors:  T C Wong; M M Lai
Journal:  Virology       Date:  1981-05       Impact factor: 3.616

7.  Qat-4 and Qat-5, new murine T-cell antigens governed by the Tla region and identified by monoclonal antibodies.

Authors:  G J Hämmerling; U Hämmerling; L Flaherty
Journal:  J Exp Med       Date:  1979-07-01       Impact factor: 14.307

8.  Preparative nonlytic separation of Lyt2+ and Lyt2- T lymphocytes, functional analyses of the separated cells and demonstration of synergy in graft-vs.-host reaction of Lyt2+ and Lyt2- cells.

Authors:  M Mage; B Mathieson; S Sharrow; L McHugh; U Hämmerling; C Kanellopoulos-Langevin; D Brideau; C A Thomas
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

9.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

10.  Studies in antibody response of mice to tumour inoculation.

Authors:  P A GORER
Journal:  Br J Cancer       Date:  1950-12       Impact factor: 7.640

View more
  16 in total

1.  Role of the NF-κB transcription factor c-Rel in the generation of CD8+ T-cell responses to Toxoplasma gondii.

Authors:  Kimberly A Jordan; Christopher D Dupont; Elia D Tait; Hsiou-Chi Liou; Christopher A Hunter
Journal:  Int Immunol       Date:  2010-11       Impact factor: 4.823

2.  c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition.

Authors:  J Bash; W X Zong; C Gélinas
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

3.  Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.

Authors:  J Nehyba; R Hrdlicková; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

4.  The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain.

Authors:  P Bull; K L Morley; M F Hoekstra; T Hunter; I M Verma
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

5.  Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation.

Authors:  Brendan A Hilliard; Nicola Mason; Lingyun Xu; Jing Sun; Salah-Eddine Lamhamedi-Cherradi; Hsiou-Chi Liou; Christopher Hunter; Youhai H Chen
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

6.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

Review 7.  Genes and genomics of autoimmune inflammation: from Rel to TRAIL.

Authors:  Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

8.  Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor.

Authors:  S Gerondakis; A Strasser; D Metcalf; G Grigoriadis; J Y Scheerlinck; R J Grumont
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

9.  A lymphoid cell-specific nuclear factor containing c-Rel-like proteins preferentially interacts with interleukin-6 kappa B-related motifs whose activities are repressed in lymphoid cells.

Authors:  K Nakayama; H Shimizu; K Mitomo; T Watanabe; S Okamoto; K Yamamoto
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

10.  v-rel induces expression of three avian immunoregulatory surface receptors more efficiently than c-rel.

Authors:  R Hrdlicková; J Nehyba; E H Humphries
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.